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BACKGROUND. A diagnosis of collagen vascular disease (CVD) may predispose to
radiotherapy (RT) toxicity. The objective of the current study was to identify
factors that influence RT toxicity in the setting of CVD.
METHODS. A total of 86 RT courses for 73 patients with CVD were delivered
between 1985 and 2005. CVD subtypes include rheumatoid arthritis (RA; 33
patients), systemic lupus erythematosus (SLE; 13 patients), scleroderma (9 patients),
dermatomyositis/polymyositis (5 patients), ankylosing spondylitis (4 patients), poly-
myalgia rheumatica/temporal arteritis (4 patients), Wegener granulomatosis
(3 patients), and mixed connective tissue disorders (MCTD)/other (2 patients).
Each patient with CVD was matched to 1 to 3 controls with respect to sex, race,
site irradiated, RT dose (2 Gray), and age (5 years).
RESULTS. There was no significant difference between CVD patients (65.1%) and
controls (72.5%) experiencing any acute toxicity. CVD patients had a higher inci-
dence of any late toxicity (29.1% vs 14%; P 5 .001), and a trend toward an
increased rate of severe late toxicity (9.3% vs 3.7%; P 5 .079). RT delivered to the
breast had increased risk of severe acute toxicity, whereas RT to the pelvis had
increased risk of severe acute and late toxicity. RT administered in the setting of
scleroderma carried a higher risk of severe late toxicity, whereas RT to SLE
patients carried a higher risk of severe acute and late toxicity.
CONCLUSIONS. Although generally well tolerated, RT in the setting of CVD
appears to carry a higher risk of late toxicity. RT to the pelvis or in the setting of
SLE or scleroderma may predispose to an even greater risk of severe toxicity.
These issues should be considered when deciding whether to offer RT for these
patients. Cancer 2008;113:648–53.  2008 American Cancer Society.
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T he decision of whether to offer therapeutic radiotherapy (RT) topatients with collagen vascular disease (CVD) continues to be a
challenging one. It is believed that CVD may predispose patients to
increased toxicity, and many practicing oncologists believe that a di-
agnosis of CVD is a relative contraindication to RT. However, to our
knowledge, the available literature on this issue has been mixed.
Early publications were largely case reports of CVD patients with
increased toxicity from RT.1-8 However, 2 separate matched control
studies failed to observe any increased risk of acute or late compli-
cations in patients with CVD versus patients without CVD.9,10 Other
publications suggested that patients with nonrheumatoid arthritis
CVD,11,12 or patients with specific subtypes of CVD, may be at
increased toxicity risk.13-15 Further complicating the issue is the
finding that some commonly prescribed medications, many of
which are used in patients with CVD, may alter the radiation toxicity
profile.16–18 The goals of this matched control study were to deter-
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mine whether patients with CVD were at a higher
risk of RT-associated toxicity compared with patients
without CVD and to identify factors that influence
radiation toxicity in the setting of CVD, with particu-
lar emphasis on medications (antirheumatic drugs,
nonsteroidal antiinflammatory drugs [NSAIDs], sta-
tins, and calcium channel blockers [CCBs]) that
when taken concurrently may alter radiation toxicity.
MATERIALS AND METHODS
After Institutional Review Board approval, 101
patients with a diagnosis of CVD treated in the
Department of Radiation Oncology at the University
of Michigan between 1985 and 2005 were identified.
A total of 116 unique RT courses were delivered to
these patients. A majority of these courses were
delivered with 3-dimensional (3D) conformal techni-
ques. Twenty-two cases were excluded because the
diagnosis of CVD was made after the completion of
RT. Of the remaining 94 RT courses, 8 courses could
not be matched with a control. This left an analyz-
able sample of 86 CVD RT courses for 73 unique
patients. Thirty-three patients had rheumatoid arthri-
tis (RA), 13 had systemic lupus erythematosus (SLE),
9 had scleroderma, 5 had dermatomyositis/polymyo-
sitis, 4 had ankylosing spondylitis, 4 had polymyalgia
rheumatica/temporal arteritis, 3 had Wegener granu-
lomatosis, and 2 had mixed connective tissue disor-
ders (MCTD)/other. Neither polymyalgia rheumatica/
temporal arteritis nor Wegener granulomatosis are
defined as a CVD; however, their inclusion was based
on the systemic vasculitis noted with these diseases
and its potential impact on RT toxicity. The mean
age of the patients at time of RT was 58.2 years
(range, 23-84 years) and the majority of patients
were women (73.3%). Sixty patients received only a
single RT course, with 13 patients receiving 2 RT
courses in this dataset. Their medical records were
reviewed for the following characteristics: age, sex,
race, CVD type and activity, date of CVD diagnosis,
concurrent medications, cancer diagnosis, chemother-
apy treatment details, site and dose schedule of RT,
acute and late toxicity, pattern of failure, and survival.
Of the total 86 RT courses, 15 were delivered to
the thorax, 14 to the skin, 12 to the head and neck,
11 to bone, 11 to the pelvis, 8 to the breast, 6 to total
body, 4 to the central nervous system, 4 to the abdo-
men, and 1 to an extremity.
Each CVD patient was then matched with a con-
trol patient without CVD for sex, race, site of disease
treated by RT, dose delivered (2 Gray [Gy]), and age
at time of RT delivery (5 years). For CVD patients
with many matching controls, the controls with the
smallest difference with regard to RT dose and age at
RT were chosen, with importance placed on mini-
mizing the difference in RT dose over the difference
in age at RT. An attempt was made to find 3 match-
ing controls for each CVD RT course. Fifty-nine
courses were matched to 3 controls, 18 courses were
matched to 2 controls, and 9 courses were matched
to a single control.
Acute toxicity was defined as toxicity from the
time of commencement of RT through Day 90 after
treatment and was scored using the Radiation Ther-
apy Oncology Group (RTOG) common toxicity crite-
ria.19 Late toxicity was defined as occurring after Day
90 posttreatment, and was scored according to the
RTOG/European Organization for Research and
Treatment of Cancer (EORTC) late radiation morbid-
ity scoring schema.20 Severe acute or late toxicity
was defined as grade 3.
Because this is a match-pairs, case-control analy-
sis, conditional logistic regression techniques were
used. Because sex, age at RT, anatomic site treated,
and RT dose were matched for by the design, these
covariates were not adjusted for in the modeling pro-
cess because their impact has been adjusted for by
the study design. The remaining covariates of interest
were as follows: concurrent infusional chemotherapy
administration, and the use of steroids, NSAIDS, sta-
tins, CCBs, antimalarial antirheumatic drugs, and
oral cytotoxic antirheumatics. Many of the medica-
tions apply only to the CVD cases and could not be
adjusted for in the overall model. The medication list
is therefore most appropriately used to help predict
toxicity in the CVD group separately.
Overall crude rates for toxicity are reported by
the anatomic site of RT delivery and by CVD subtype
of the cases. Although these rates are instructive, for-
mal comparison at the matched case-control level
has not been attempted because of the small sample
size. Formal comparisons were limited to the entire
population. P values .05 are considered statistically
significant.
There were 4 endpoints of interest: any acute




With a median follow-up time of 1.3 years for each
group, overall, there was no significant difference
noted with regard to the incidence of acute toxicity
between CVD and control cases, with 65.1% of CVD
patients experiencing any acute toxicity, compared
with 72.5% of control patients (Table 1). The inci-
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dence of severe acute toxicity was similar in both
groups (10.5% vs 10.4%).
Late Toxicity
Overall, patients with a CVD diagnosis had a signifi-
cantly higher incidence of any late toxicity (29.1% vs
14%; P 5 .001), with a trend toward increased severe
late toxicity (9.3% vs 3.7%; P 5 .079) (Table 1).
Toxicity by Irradiated Site
Although overall there was no significant difference
noted with regard to the incidence of acute toxicity,
CVD patients treated with RT to some anatomic sites
were found to have a higher rate of severe acute tox-
icity (Table 2). RT to CVD patients produced higher
crude rates of grade 3 acute toxicity when delivered
to the breast (2 patients [25%] vs 0 patients [0%]) or
pelvis (4 patients [36%] vs 3 patients [11%]). For the
2 CVD patients with severe breast acute toxicity, tox-
icity consisted of grade 3 skin desquamation. For the
4 CVD patients with severe pelvic acute toxicity, 3
had grade 3 skin desquamation alone, whereas the
fourth patient had grade 3 skin desquamation, cysti-
tis, and diarrhea/dehydration. However, given the
small sample sizes per group and the matched case-
control design of the study, formal statistical compar-
isons were not attempted.
RT to several anatomic sites produced a higher
crude rate of any late toxicity in CVD patients (Table
2), including the head and neck (6 patients [50%] vs
8 patients [25%]), pelvis (7 patients [64%] vs 7
patients [25%]), skin (4 patients [29%] vs 0 patients
[0%]), and thorax (4 patients [27%] vs 5 patients
TABLE 1





0 1 2 3 4 5 Py Py
Acute Toxicity*
CVD cases 30 (34.9) 19 (22.1) 28 (32.6) 9 (10.5) 0 0 — —
Control
cases 61 (27.5) 63 (28.4) 75 (33.8) 23 (10.4) 0 0 .97 .075
Late Toxicity{
CVD cases 61 (70.9) 10 (11.6) 7 (8.1) 4 (4.7) 2 (2.3) 2 (2.3) — —
Control
cases 191 (86.0) 14 (6.3) 9 (4.1) 7 (3.2) 1 (0.5) 0 .0010 .079
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy throughDay 90 after treat-
ment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
y Exact P value was derived from conditional logistic regression analysis.
{ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to
the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation mor-
bidity scoring schema.20
TABLE 2




0 1 2 3 4 5
Bone
Cases (n 5 11) 11 (100.0) 0 0 0 0 0
Controls (n 5 28) 20 (71.4) 4 (14.3) 4 (14.3) 0 0 0
Breast
Cases (n 5 8) 1 (12.5) 1 (12.5) 4 (50.0) 2 (25.0) 0 0
Controls (n 5 20) 0 6 (30.0) 14 (70.0) 0 0 0
Head and neck
Cases (n 5 12) 0 4 (33.3) 6 (50.0) 2 (16.7) 0 0
Controls (n 5 32) 5 (15.6) 8 (25.0) 12 (37.5) 7 (21.9) 0 0
Pelvis
Cases (n 5 11) 0 1 (9.1) 6 (54.6) 4 (36.4) 0 0
Controls (n 5 28) 2 (7.1) 7 (25.0) 16 (57.1) 3 (10.7) 0 0
Skin
Cases (n 5 14) 0 10 (71.4) 4 (28.6) 0 0 0
Controls (n 5 35) 1 (2.9) 17 (48.6) 14 (40.0) 3 (8.6) 0 0
Thorax
Cases (n 5 15) 6 (40.0) 3 (20.0) 6 (40.0) 0 0 0
Controls (n 5 41) 14 (34.2) 12 (29.3) 8 (19.5) 7 (17.1) 0 0
Other sitesy
Cases (n 5 15) 12 (80.0) 0 3 (20.0) 0 0 0
Controls (n 5 38) 19 (50.0) 9 (23.7) 6 (15.8) 4 (10.5) 0 0
Late toxicity grade{
0 1 2 3 4 5
Bone
Cases (n 5 11) 11 (100.0) 0 0 0 0 0
Controls (n 5 28) 27 (96.4) 1 (3.6) 0 0 0 0
Breast
Cases (n 5 8) 5 (62.5) 1 (12.5) 2 (25.0) 0 0 0
Controls (n 5 20) 13 (65.0) 4 (20.0) 3 (15.0) 0 0 0
Head and neck
Cases (n 5 12) 6 (50.0) 2 (16.7) 2 (16.7) 2 (16.7) 0 0
Controls (n 5 32) 24 (75.0) 2 (6.3) 2 (6.3) 3 (9.4) 1 (3.1) 0
Pelvis
Cases (n 5 11) 4 (36.4) 2 (18.2) 1 (9.1) 1 (9.1) 2 (18.2) 1 (9.1)
Controls (n 5 28) 21 (75.0) 2 (7.1) 3 (10.7) 2 (7.1) 0 0
Skin
Cases (n 5 14) 10 (71.4) 4 (28.6) 0 0 0 0
Controls (n 5 35) 35 (100.0) 0 0 0 0 0
Thorax
Cases (n 5 15) 11 (73.3) 1 (6.7) 2 (13.3) 1 (6.7) 0 0
Controls (n 5 41) 36 (87.8) 4 (9.8) 1 (2.4) 0 0 0
Other sitesy
Cases (n 5 15) 14 (93.3) 0 0 0 0 1 (6.7)
Controls (n 5 38) 36 (94.7) 0 0 2 (5.3) 0 0
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90
after treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common
toxicity criteria.19
y Other sites included the abdomen, central nervous system, extremities, and total body.
{ Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according
to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation
morbidity scoring schema.20
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[12%]). The incidence of severe toxicity was greater
mainly only in the pelvis subgroup, with 4 CVD
patients (36%) experiencing grade 31 toxicity (con-
sisting of small bowel ulceration and dysuria),
including 1 grade 5 event (intestinal perforation),
versus 2 in the control group with severe toxicity
(7%). RT to the other anatomic sites was found to be
equally well tolerated by both CVD and control
patients.
Toxicity by CVD Subtype
Table 3 summarizes the toxicity information when
separated by CVD subtype. The only patients who
had an appreciably higher crude incidence of any
acute toxicity when compared with controls were
patients with SLE (88.2% vs 76.2%). Patients with SLE
were also the only CVD subset found to have a
higher crude risk of severe acute toxicity (29.4% vs
11.9%), which was the highest rate of severe acute
toxicity noted among all CVD subtypes. Otherwise,
severe acute toxicity was uncommon.
Compared with controls, the incidence of any
late toxicity was observed to be higher in several
CVD subtypes: RA (29.7% vs 13.9%), SLE (41.2% vs
19.1%), dermatomyositis/polymyositis (16.7% vs
8.3%), polymyalgia rheumatica/temporal arteritis
(28.6% vs 5.0%), and MCTD/other (50.0% vs 16.7%).
The incidence of severe late toxicity was generally
low among both CVD and control patients; however,
patients with SLE (35.3% vs 4.8%) and scleroderma
(10.0% vs 3.9%) had a higher risk of severe late toxic-
ity versus controls.
Concomitant Medication Use by CVD Patients
Table 4 lists several types of medications and their
frequencies of use by CVD patients. Tables 5 and 6
list the distribution of acute and late toxicities for
CVD cases, respectively. None of the following medi-
cations was found to be significantly associated with
a risk of any acute or late toxicity: corticosteroids,
NSAIDs, statins, CCBs, and antimalarials. The use of
oral cytotoxic, rheumatologic agents was found to be
significantly associated with a decreased risk of any
acute toxicity (P 5 .0263), and concurrent infusional
chemotherapy was found to be significantly associated
with an increased risk of severe acute toxicity (P 5 .0022).
Chemotherapy was the only concomitant medication that
was found to be associated with increased risk of any
(P 5 .009) or severe (P 5 .009) late toxicity.
TABLE 3
Distribution of Toxicity (Percent) by CVD Case/Control Status, by CVD Subtype
CVD Subtype
Acute* Latey
Any Severe Any Severe
CVD Control CVD Control CVD Control CVD Control
Rheumatoid arthritis 64.9 76.2 10.8 9.9 29.7 13.9 2.7 4.0
Systemic lupus erythematosus 88.2 76.2 29.4 11.9 41.2 19.1 35.3 4.8
Dermatomyositis/polymyositis 66.7 91.7 0 8.3 16.7 8.3 0 0
Ankylosing spondylitis 0 0 0 0 0 0 0 0
Wegener granulomatosis 100 100 0 16.7 33.3 33.3 0 0
Scleroderma 30.0 53.9 0 11.5 20.0 15.4 10.0 3.9
Polymyalgia rheumatica/temporal arteritis 85.7 80.0 0 10.0 28.6 5.0 0 5.0
Mixed connective tissue disorder/other 50.0 83.3 0 16.7 50.0 16.7 0 0
CVD indicates collagen vascular disease.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 after treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity criteria.19
y Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation morbidity
scoring schema.20
TABLE 4









Oral cytotoxic, antirheumatic drugs 17 19.8
Statins 13 15.1
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal antiinflammatory drugs; CCB, cal-
cium-channel blocker.
* Concurrent with radiotherapy.
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DISCUSSION
Delivering RT to patients with CVD continues to be a
challenging clinical dilemma for radiation oncolo-
gists. The existing literature is difficult to interpret
because of the heterogeneity in CVD subtype and ac-
tivity, the variations in RT dose and site of treatment,
as well as the potential role of concomitant medica-
tions in altering toxicity. Morris and Powell11
reported that severe late effects were associated with
CVD other than RA, a finding that was also sup-
ported by a meta-analysis by Chon and Loeffler.12
Other studies suggest that a diagnosis of sclero-
derma13,14 or lupus15 may increase the risk of RT-
associated toxicity. However, 2 separate matched
control studies failed to observe any increased risk of
acute or late complications in patients with CVD ver-
sus patients without CVD.9,10
To our knowledge, the current study is the largest
matched-control analysis of acute and late complica-
tions in patients with CVDs receiving RT. Unlike the
other matched control studies,9,10 we did find that a
diagnosis of a CVD increased the risk of having any
late toxicity, with a trend toward increased severe
late toxicity. We also examined a variety of factors
that can potentially influence the toxicity profile. We
found that there was little difference in toxicity pro-
file for most irradiated sites. However, RT to the
breast and pelvis were possible exceptions. Greater
than one-third of all patients with RT to the pelvis
experienced severe acute and late toxicity. Similar to
previous studies,11–15 we also found that patients
with scleroderma or SLE were at the highest risk of
experiencing severe acute or late complications. Mor-
ris and Powell11 previously examined the impact of
various medications on RT toxicity and found that
patients undergoing NSAID therapy at the time of RT
had a lower risk of late effects. Our findings demon-
strated that most commonly used medications did
not influence RT toxicity, but that concurrent chemo-
therapy was associated with increased severe acute
and late toxicity.
There are strengths and limitations to the current
study. Similar to previous publications on the sub-
ject, we were limited by the heterogeneity of CVD
subtype, which thereby limited the number of
patients analyzed for each subtype. Toxicity data was
TABLE 6
Medications and Treatments by Late Toxicity*: CVD Cases Only
Frequency
(Percent)
Toxicity grade Any Severe
0 1 2 3 4 5 Py Py
Corticosteroids
No 37 (68.5) 6 (11.1) 5 (9.3) 3 (5.6) 2 (3.7) 1 (1.9)
Yes 24 (75.0) 4 (12.5) 2 (6.3) 1 (3.1) 0 1 (3.1) .63 .70
NSAIDs
No 37 (71.2) 5 (9.6) 6 (11.5) 3 (5.8) 0 1 (1.9)
Yes 24 (70.6) 5 (14.7) 1 (2.9) 1 (2.9) 2 (5.9) 1 (2.9) 1 .71
Statins
No 52 (71.2) 8 (11.0) 6 (8.2) 3 (4.1) 2 (2.7) 2 (2.7)
Yes 9 (69.2) 2 (15.4) 1 (7.7) 1 (7.7) 0 0 1 1
CCB
No 47 (71.2) 7 (10.6) 6 (9.1) 4 (6.1) 0 2 (3.0)
Yes 14 (70.0) 3 (15.0) 1 (5.0) 0 2 (10.0) 0 1 1
Antimalarials
No 45 (73.8) 6 (9.8) 6 (9.8) 3 (4.9) 0 1 (1.6)
Yes 16 (64.0) 4 (16.0) 1 (4.0) 1 (4.0) 2 (8.0) 1 (1.0) .44 .22
Oral cytotoxics
No 48 (69.6) 7 (10.1) 7 (10.1) 4 (5.8) 2 (2.9) 1 (1.5)
Yes 13 (76.5) 3 (17.6) 0 0 0 1 (5.9) .77 1
Infusional chemotherapy
No 53 (77.9) 8 (11.8) 4 (5.9) 2 (2.9) 0 1 (1.5)
Yes 8 (44.4) 2 (11.1) 3 (16.7) 2 (11.1) 2 (11.1) 1 (5.6) .0087 .0089
CVD indicates collagen vascular disease; NSAIDs, nonsteroidal anti-inflammatory drugs; CCB, cal-
cium channel blocker.
* Late toxicity was defined as that occurring after Day 90 after treatment, and was scored according
to the RTOG/European Organization for Research and Treatment of Cancer (EORTC) late radiation
morbidity scoring schema.20
y P value was derived using the Fisher exact test.
TABLE 5
Medications and Treatments by Acute Toxicity*: CVD Cases Only
Frequency
(Percent)
Toxicity grade Any Severe
0 1 2 3 Py Py
Corticosteroids
No 22 (40.7) 11 (20.4) 14 (25.9) 7 (13.0)
Yes 8 (25.0) 8 (25.0) 14 (43.8) 2 (6.3) .17 .47
NSAIDS
No 17 (32.7) 11 (21.2) 18 (34.6) 6 (11.5)
Yes 13 (38.2) 8 (23.5) 10 (29.4) 3 (8.8) .65 1
Statins
No 28 (38.4) 13 (17.8) 23 (31.5) 9 (12.3)
Yes 2 (6.7) 6 (46.2) 5 (38.5) 0 .13 .34
CCB
No 23 (34.9) 15 (22.7) 21 (31.8) 7 (10.6)
Yes 7 (35.0) 4 (20.0) 7 (35.0) 2 (10.0) 1 1
Antimalarials
No 24 (39.3) 13 (21.3) 19 (31.2) 5 (8.2)
Yes 6 (24.0) 6 (24.0) 9 (36.0) 4 (16.0) .22 .44
Oral cytotoxics
No 20 (29.0) 16 (23.2) 25 (36.2) 8 (11.6)
Yes 10 (58.8) 3 (17.7) 3 (17.7) 1 (5.9) .026 .68
Infusional chemotherapy
No 23 (33.8) 19 (27.9) 23 (33.8) 3 (4.4)
Yes 7 (38.9) 0 5 (27.8) 6 (33.3) .78 .0022
CVD indicates collagen vascular disease; NSAID, nonsteroidal anti-inflammatory drug; CCB, calcium-
channel blocker.
* Acute toxicity was defined as toxicity from the commencement of radiotherapy through Day 90 af-
ter treatment, and was scored using the Radiation Therapy Oncology Group (RTOG) common toxicity
criteria.19
y P value was derived using the Fisher exact test.
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collected retrospectively, and there was no reliable
method with which to assess CVD activity status at
the time of RT. We were unable to analyze dose inde-
pendently as a variable. Because dose was dependent
on treatment site, it would require a range of RT
doses at a given site and a reasonable sample size to
make dose-specific comments. This was beyond the
scope of our institutional patient experience. The
strengths of this study lie in the total number of
patients analyzed and the use of a 3:1 control:case
match by age, sex, RT dose, and anatomic site. This
approach allows for a more robust analysis of the
risk profile, allowing us to determine that patients
with scleroderma and SLE are at increased risk of
severe toxicity. Although other CVD subtypes may
also predispose to toxicity, the same conclusions
cannot be made because of the limited sample size
of patients with these subtypes in our study. It is also
important to note that with a median follow-up of
1.3 years, the toxicity rates reported in our study
may be underestimating the true rate of late toxicity.
Another unique aspect of this study is the compre-
hensive analysis of concomitant medication use and
its impact on the RT toxicity profile. Given the heter-
ogeneity observed in CVD subtype and disease activ-
ity, and other variables such as RT dose and site, it is
not likely that we will ever have prospective con-
trolled data for these questions.
In summary, although a diagnosis of a CVD
appears to predispose patients to a greater risk of
late RT toxicity, treatment is generally well tolerated,
with a relatively low incidence of severe acute or late
toxicity. Other factors can impact the risk of toxicity,
including CVD subtype, site of irradiation, RT dose,
and the use of concurrent chemotherapy. In patients
who may be at particularly high risk because of CVD
subtype or RT site, careful attention to issues of tox-
icity is required. Treatment modifications such as
reduction of fraction size, twice-daily treatment, or
reduction of total dose for these patients may be
considered. These factors should be taken into con-
sideration in the risk-benefit analysis at the time of
consultation.
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